Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
Legend Biotech (NASDAQ: LEGN) will host an investor conference call at 8:00 am ET on Tuesday, May 12, 2026 to review first quarter 2026 financial results.
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) will host an investor conference call at 8:00 am ET on Tuesday, May 12, 2026 to review first quarter 2026 financial results. Senior management will provide an overview of quarterly financial performance via live audio webcast.
A replay and the earnings press release will be available in the Investor Relations section under Events and Presentation approximately two hours after the call concludes.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LEGN
In the Apr 28 session, LEGN declined 0.38%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference call time
- 8:00 am ET
- Scheduled investor call on May 12, 2026
- Call date
- May 12, 2026
- First quarter 2026 results conference call
- Replay timing
- two hours
- Approximate delay before webcast replay and release posted
Previous Conferences,earnings Reports
-
Scheduled Q4 and full-year 2025 earnings call with webcast details.
-
Announced Q3 2025 results conference call and replay availability.
-
Set date and time for Q2 2025 earnings call and webcast access.
-
Outlined logistics for Q1 2025 earnings call for investors.
-
Announced Q4 and full-year 2024 earnings call timetable and webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results.
During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance.
Investors and other interested parties may access the live audio webcast via this weblink.
A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentation approximately two hours after the conclusion of the call.
ABOUT LEGEND BIOTECH
With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.